Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

Zúñiga believes that interventions that target LDHB or related metabolic pathways could be explored as a way to counteract ...

(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy ...

Researchers have uncovered critical mechanisms linked to metabolic insufficiencies that underlie plasmacytoid dendritic cell ...

Cancer cells are known to favor aerobic glycolysis for energy production, a phenomenon termed the Warburg effect.

All patients with malignancies referred to the PDC will be assessed in a multidisciplinary fashion, receive genetic tumor typing for personalized treatment, and have access to multiple clinical trials ...

PDHX acetylation promotes tumor progression by disrupting PDC assembly and activating lactylation-mediated gene expression.

Avacta Group plc ( ($GB:AVCT) ) has issued an announcement. Avacta Therapeutics announced its participation in the 2025 Leerink Global Healthcare ...

AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present ...